Last reviewed · How we verify
Nicotine Patch + Nicotine Gum
Nicotine Patch + Nicotine Gum is a Nicotinic acetylcholine receptor agonist Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved for Smoking cessation in adults.
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine patches and nicotine gum are small molecule interventions used to treat nicotine addiction, as indicated by ClinicalTrials.gov. They are used to help manage withdrawal symptoms and cravings associated with smoking cessation, according to their verified use in clinical trials.
At a glance
| Generic name | Nicotine Patch + Nicotine Gum |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine is a psychoactive alkaloid that activates nicotinic acetylcholine receptors, particularly in the ventral tegmental area and nucleus accumbens, which are involved in reward and addiction pathways. By providing nicotine through transdermal (patch) and oral (gum) routes, the combination therapy delivers the drug at different rates to manage both acute cravings and sustained withdrawal symptoms. This dual-delivery approach helps smokers transition away from cigarette smoking by satisfying nicotine dependence while avoiding the harmful combustion byproducts of tobacco.
Approved indications
- Smoking cessation in adults
Common side effects
- Skin irritation at patch application site
- Mouth irritation from gum
- Nausea
- Dizziness
- Headache
- Insomnia
- Hiccups
Key clinical trials
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- ACT Lung Health Intervention: Phase Two (NA)
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- Mobile Contingency Management for Smoking Cessation (NA)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine Patch + Nicotine Gum CI brief — competitive landscape report
- Nicotine Patch + Nicotine Gum updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI
Frequently asked questions about Nicotine Patch + Nicotine Gum
What is Nicotine Patch + Nicotine Gum?
How does Nicotine Patch + Nicotine Gum work?
What is Nicotine Patch + Nicotine Gum used for?
Who makes Nicotine Patch + Nicotine Gum?
What drug class is Nicotine Patch + Nicotine Gum in?
What development phase is Nicotine Patch + Nicotine Gum in?
What are the side effects of Nicotine Patch + Nicotine Gum?
What does Nicotine Patch + Nicotine Gum target?
Related
- Drug class: All Nicotinic acetylcholine receptor agonist drugs
- Target: All drugs targeting Nicotinic acetylcholine receptors
- Manufacturer: University of Wisconsin, Madison — full pipeline
- Therapeutic area: All drugs in Addiction Medicine / Smoking Cessation
- Indication: Drugs for Smoking cessation in adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing